Frank L J Visseren

List of Publications by Year in Descending Order

267 papers	11,813 citations	44 h-index	103 g-index
285 ext. papers	16,276 ext. citations	5.7 avg, IF	6.17 L-index

#	Paper	IF	Citations
267	Population median imputation was noninferior to complex approaches for imputing missing values in cardiovascular prediction models in clinical practice.. *Journal of Clinical Epidemiology*, **2022**,	5.7	2
266	Targeted proteomics improves cardiovascular risk prediction in secondary prevention.. *European Heart Journal*, **2022**,	9.5	3
265	Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease: the updated SMART2 algorithm.. *European Heart Journal*, **2022**,	9.5	1
264	Relation Between Plasma Proteomics Analysis and Major Adverse Cardiovascular Events in Patients With Stable Coronary Artery Disease.. *Frontiers in Cardiovascular Medicine*, **2022**, 9, 731325	5.4	0
263	The Ten commandments for the 2021 ESC Guidelines on CVD prevention.. *European Heart Journal*, **2022**, 43, 174-176	9.5	0
262	Screen-detected abnormal ankle brachial index: A risk indicator for future cardiovascular morbidity and mortality in patients with manifest cardiovascular disease.. *PLoS ONE*, **2022**, 17, e0265050	3.7	0
261	The relation between urinary sodium and potassium excretion and risk of cardiovascular events and mortality in patients with cardiovascular disease.. *PLoS ONE*, **2022**, 17, e0265429	3.7	2
260	Modifiable risk factors in adults with and without prior cardiovascular disease: findings from the Indonesian National Basic Health Research.. *BMC Public Health*, **2022**, 22, 660	4.1	0
259	Chronic kidney disease and atrial fibrillation: A dangerous combination.. *PLoS ONE*, **2022**, 17, e0266046	3.7	1
258	Use of lipid-lowering therapy after ischaemic stroke and expected benefit from intensification of treatment.. *Open Heart*, **2022**, 9,	3	1
257	Number of measurement days needed for obtaining a reliable estimate of home blood pressure and hypertension status.. *Blood Pressure*, **2022**, 31, 100-108	1.7	1
256	Lifestyle changes and kidney function: A ten year follow-up study in patients with manifest cardiovascular disease.. *European Journal of Clinical Investigation*, **2022**, e13814	4.6	
255	Risk Factor Clusters and Cardiovascular Disease in High-Risk Patients: The UCC-SMART Study.. *Global Heart*, **2021**, 16, 85	2.9	1
254	Low-grade inflammation as a risk factor for cardiovascular events and all-cause mortality in patients with type 2 diabetes. *Cardiovascular Diabetology*, **2021**, 20, 220	8.7	5
253	Allopurinol to reduce cardiovascular morbidity and mortality: A systematic review and meta-analysis. *PLoS ONE*, **2021**, 16, e0260844	3.7	3
252	Impact of a Patient's Baseline Risk on the Relative Benefit and Harm of a Preventive Treatment Strategy: Applying Trial Results in Clinical Decision Making.. *Journal of the American Heart Association*, **2021**, e017605	6	
251	Insulin resistance and risk of vascular events, interventions and mortality in type 1 diabetes. *European Journal of Endocrinology*, **2021**, 185, 831-840	6.5	1

250	Prediction models for recurrence and bleeding in patients with venous thromboembolism: A systematic review and critical appraisal. *Thrombosis Research*, **2021**, 199, 85-96	8.2	2
249	End-stage kidney disease in patients with clinically manifest vascular disease; incidence and risk factors: results from the UCC-SMART cohort study. *Journal of Nephrology*, **2021**, 34, 1511-1520	4.8	1
248	Systematic Coronary Risk Evaluation (SCORE): JACC Focus Seminar 4/8. *Journal of the American College of Cardiology*, **2021**, 77, 3046-3057	15.1	
247	Comment on Vistisen et al. A Validated Prediction Model for End-Stage Kidney Disease in Type 1 Diabetes. Diabetes Care 2021;44:901-907. *Diabetes Care*, **2021**, 44, e139	14.6	1
246	Adiposity and the development of dyslipidemia in APOE ε2 homozygous subjects: A longitudinal analysis in two population-based cohorts. *Atherosclerosis*, **2021**, 325, 57-62	3.1	0
245	SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. *European Heart Journal*, **2021**, 42, 2439-2454	9.5	58
244	SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions. *European Heart Journal*, **2021**, 42, 2455-2467	9.5	31
243	Systematic Coronary Risk Evaluation (SCORE): JACC Focus Seminar 4/8. *Journal of the American College of Cardiology*, **2021**, 77, 3046-3057	15.1	6
242	Apparent treatment resistant hypertension and the risk of recurrent cardiovascular events and mortality in patients with established vascular disease. *International Journal of Cardiology*, **2021**, 334, 135-141	3.2	4
241	The relation between VLDL-cholesterol and risk of cardiovascular events in patients with manifest cardiovascular disease. *International Journal of Cardiology*, **2021**, 322, 251-257	3.2	5
240	Plasma Trough Concentrations of Antihypertensive Drugs for the Assessment of Treatment Adherence: A Meta-Analysis. *Hypertension*, **2021**, 77, 85-93	8.5	1
239	Applicability of Blood Pressure-Lowering Drug Trials to Real-World Patients With Cardiovascular Disease. *Hypertension*, **2021**, 77, 357-366	8.5	
238	Platelet aggregation inhibitor prescription for newly diagnosed peripheral arterial disease in the Netherlands: a cohort study. *BMJ Open*, **2021**, 11, e041715	3	1
237	Added value of cardiovascular calcifications for prediction of recurrent cardiovascular events and cardiovascular interventions in patients with established cardiovascular disease. *International Journal of Cardiovascular Imaging*, **2021**, 37, 2051-2061	2.5	3
236	Relationship between classic vascular risk factors and cumulative recurrent cardiovascular event burden in patients with clinically manifest vascular disease: results from the UCC-SMART prospective cohort study. *BMJ Open*, **2021**, 11, e038881	3	0
235	Communicating personalised statin therapy-effects as 10-year CVD-risk or CVD-free life-expectancy: does it improve decisional conflict? Three-armed, blinded, randomised controlled trial. *BMJ Open*, **2021**, 11, e041673	3	0
234	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. *European Heart Journal*, **2021**, 42, 3227-3337	9.5	358
233	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. *European Journal of Preventive Cardiology*, **2021**,	3.9	31

232	Risk Stratification in Patients with Ischemic Stroke and Residual Cardiovascular Risk with Current Secondary Prevention. *Clinical Epidemiology*, **2021**, 13, 813-823	5.9	2
231	Evaluation of contemporary treatment of high- and very high-risk patients for the prevention of cardiovascular events in Europe Methodology and rationale for the multinational observational SANTORINI study. *Atherosclerosis Plus*, **2021**, 43, 24-30		2
230	Psychosocial factors and cancer incidence (PSY-CA): Protocol for individual participant data meta-analyses. *Brain and Behavior*, **2021**, 11, e2340	3.4	2
229	External applicability of SGLT2 inhibitor cardiovascular outcome trials to patients with type 2 diabetes and cardiovascular disease. *Cardiovascular Diabetology*, **2021**, 20, 181	8.7	
228	Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk: Meta-Analysis of 119 Clinical Trials Involving 100 667 Patients. *Circulation*, **2020**, 142, 621-642	16.7	88
227	Multifocal cardiovascular calcification in patients with established cardiovascular disease; prevalence, risk factors, and relation with recurrent cardiovascular disease. *IJC Heart and Vasculature*, **2020**, 27, 100499	2.4	3
226	Circulating Neutrophils Do Not Predict Subclinical Coronary Artery Disease in Women with Former Preeclampsia. *Cells*, **2020**, 9,	7.9	2
225	Development of a clinical decision tool to reduce diagnostic testing for primary aldosteronism in patients with difficult-to-control hypertension. *BMC Endocrine Disorders*, **2020**, 20, 56	3.3	0
224	Would treatment decisions about secondary prevention of CVD based on estimated lifetime benefit rather than 10-year risk reduction be cost-effective?. *Diagnostic and Prognostic Research*, **2020**, 4, 4	5.5	1
223	Apparent therapy-resistant hypertension as risk factor for the development of type 2 diabetes mellitus. *Journal of Hypertension*, **2020**, 38, 45-51	1.9	2
222	Data mining information from electronic health records produced high yield and accuracy for current smoking status. *Journal of Clinical Epidemiology*, **2020**, 118, 100-106	5.7	9
221	Treatment of hypercholesterolaemia in older adults calls for a patient-centred approach. *Heart*, **2020**, 106, 261-266	5.1	5
220	Association of Factor V Leiden With Subsequent Atherothrombotic Events: A GENIUS-CHD Study of Individual Participant Data. *Circulation*, **2020**, 142, 546-555	16.7	5
219	Prediction of Lifetime and 10-Year Risk of Cancer in Individual Patients With Established Cardiovascular Disease. *JACC: CardioOncology*, **2020**, 2, 400-410	3.8	1
218	Prediction of individualized lifetime benefit from cholesterol lowering, blood pressure lowering, antithrombotic therapy, and smoking cessation in apparently healthy people. *European Heart Journal*, **2020**, 41, 1190-1199	9.5	33
217	Risk prediction tools in cardiovascular disease prevention: A report from the ESC Prevention of CVD Programme led by the European Association of Preventive Cardiology (EAPC) in collaboration with the Acute Cardiovascular Care Association (ACCA) and the Association of Cardiovascular Nursing and Allied Professions (ACNAP). *European Heart Journal. Acute Cardiovascular Care*, **2020**, 9, 522-532	4.3	15
216	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. *European Heart Journal*, **2020**, 41, 111-188	9.5	2236
215	Cardiovascular risk factors and the risk of major adverse limb events in patients with symptomatic cardiovascular disease. *Heart*, **2020**, 106, 1686-1692	5.1	4

214	Cardiovascular risk prediction tools made relevant for GPs and patients. *Heart*, **2020**,	5.1	2
213	The relation between systemic inflammation and incident cancer in patients with stable cardiovascular disease: a cohort study. *European Heart Journal*, **2019**, 40, 3901-3909	9.5	25
212	2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. *Atherosclerosis*, **2019**, 290, 140-205	3.1	259
211	Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial. *European Heart Journal*, **2019**, 40, 3771-3778a	9.5	19
210	Choosing the right strategy based on individualized treatment effect predictions: combination versus sequential chemotherapy in patients with metastatic colorectal cancer. *Acta Oncologica*, **2019**, 58, 326-333	3.2	1
209	Risk prediction tools in cardiovascular disease prevention: A report from the ESC Prevention of CVD Programme led by the European Association of Preventive Cardiology (EAPC) in collaboration with the Acute Cardiovascular Care Association (ACCA) and the Association of Cardiovascular Nursing and Allied Professions (ACNAP). *European Journal of Preventive Cardiology*, **2019**, 26, 1534-1544	3.9	33
208	Smoking cessation and risk of recurrent cardiovascular events and mortality after a first manifestation of arterial disease. *American Heart Journal*, **2019**, 213, 112-122	4.9	17
207	The effect of computerized decision support systems on cardiovascular risk factors: a systematic review and meta-analysis. *BMC Medical Informatics and Decision Making*, **2019**, 19, 108	3.6	20
206	Mediation analysis of the relationship between type 2 diabetes and cardiovascular events and all-cause mortality: Findings from the SMART cohort. *Diabetes, Obesity and Metabolism*, **2019**, 21, 1935-1943	6.7	10
205	Comorbidity in patients with cardiovascular disease in primary care: a cohort study with routine healthcare data. *British Journal of General Practice*, **2019**, 69, e398-e406	1.6	22
204	Subsequent Event Risk in Individuals With Established Coronary Heart Disease. *Circulation Genomic and Precision Medicine*, **2019**, 12, e002470	5.2	13
203	Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events. *Circulation Genomic and Precision Medicine*, **2019**, 12, e002471	5.2	14
202	Individual Treatment Effect Estimation of 2 Doses of Dabigatran on Stroke and Major Bleeding in Atrial Fibrillation. *Circulation*, **2019**, 139, 2846-2856	16.7	9
201	Severe hypertriglyceridaemia and pancreatitis in a patient with lipoprotein lipase deficiency based on mutations in lipoprotein lipase (LPL) and apolipoprotein A5 (APOA5) genes. *BMJ Case Reports*, **2019**, 12,	0.9	3
200	Limited benefit of haemoglobin glycation index as risk factor for cardiovascular disease in type 2 diabetes patients. *Diabetes and Metabolism*, **2019**, 45, 254-260	5.4	7
199	The prevalence of pseudoxanthoma elasticum: Revised estimations based on genotyping in a high vascular risk cohort. *European Journal of Medical Genetics*, **2019**, 62, 90-92	2.6	14
198	Heterogeneity of Treatment Effects From an Intensive Lifestyle Weight Loss Intervention on Cardiovascular Events in Patients With Type 2 Diabetes: Data From the Look AHEAD Trial. *Diabetes Care*, **2019**, 42, 1988-1994	14.6	8
197	Risk prediction tools in cardiovascular disease prevention: A report from the ESC Prevention of CVD Programme led by the European Association of Preventive Cardiology (EAPC) in collaboration with the Acute Cardiovascular Care Association (ACCA) and the Association of Cardiovascular Nursing and Allied Professions (ACNAP). *European Journal of Cardiovascular Nursing*, **2019**, 18, 534-544	3.3	7

196	Normal-range thyroid-stimulating hormone levels and cardiovascular events and mortality in type 2 diabetes. *Diabetes Research and Clinical Practice*, **2019**, 157, 107880	7.4	0
195	Prevalence of potential modifiable factors of hypertension in patients with difficult-to-control hypertension. *Journal of Hypertension*, **2019**, 37, 398-405	1.9	4
194	Adiposity and risk of decline in glomerular filtration rate: meta-analysis of individual participant data in a global consortium. *BMJ, The*, **2019**, 364, k5301	5.9	85
193	Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500 000 patients with Type 2 diabetes mellitus. *European Heart Journal*, **2019**, 40, 2899-2906	9.5	28
192	Relationship of Estimated GFR and Albuminuria to Concurrent Laboratory Abnormalities: An Individual Participant Data Meta-analysis in a Global Consortium. *American Journal of Kidney Diseases*, **2019**, 73, 206-217	7.4	25
191	Prevalence of Subclinical Coronary Artery Disease Assessed by Coronary Computed Tomography Angiography in 45- to 55-Year-Old Women With a History of Preeclampsia. *Circulation*, **2018**, 137, 877-879	16.7	37
190	Predicting the Effect of Fenofibrate on Cardiovascular Risk for Individual Patients With Type 2 Diabetes. *Diabetes Care*, **2018**, 41, 1244-1250	14.6	11
189	Etidronate for Prevention of Ectopic Mineralization in Patients With Pseudoxanthoma Elasticum. *Journal of the American College of Cardiology*, **2018**, 71, 1117-1126	15.1	63
188	Estimated individual lifetime benefit from PCSK9 inhibition in statin-treated patients with coronary artery disease. *Heart*, **2018**, 104, 1699-1705	5.1	11
187	Arterial stiffening and thickening in patients with pseudoxanthoma elasticum. *Atherosclerosis*, **2018**, 270, 160-165	3.1	7
186	Cost-effectiveness of PCSK9 inhibition in addition to standard lipid-lowering therapy in patients at high risk for vascular disease. *International Journal of Cardiology*, **2018**, 253, 148-154	3.2	18
185	Predicting timing of clinical outcomes in patients with chronic kidney disease and severely decreased glomerular filtration rate. *Kidney International*, **2018**, 93, 1442-1451	9.9	67
184	Decline in risk of recurrent cardiovascular events in the period 1996 to 2014 partly explained by better treatment of risk factors and less subclinical atherosclerosis. *International Journal of Cardiology*, **2018**, 251, 96-102	3.2	9
183	The relation between body fat distribution, plasma concentrations of adipokines and the metabolic syndrome in patients with clinically manifest vascular disease. *European Journal of Preventive Cardiology*, **2018**, 25, 1548-1557	3.9	21
182	Combined use of polypill components in patients with type 2 diabetes mellitus. *European Journal of Preventive Cardiology*, **2018**, 25, 1523-1531	3.9	4
181	Four ECG left ventricular hypertrophy criteria and the risk of cardiovascular events and mortality in patients with vascular disease. *Journal of Hypertension*, **2018**, 36, 1865-1873	1.9	7
180	Random measurement error: Why worry? An example of cardiovascular risk factors. *PLoS ONE*, **2018**, 13, e0192298	3.7	27
179	Apparent resistant hypertension and the risk of vascular events and mortality in patients with manifest vascular disease. *Journal of Hypertension*, **2018**, 36, 143-150	1.9	12

178	Estimated Life Expectancy Without Recurrent Cardiovascular Events in Patients With Vascular Disease: The SMART-REACH Model. *Journal of the American Heart Association*, **2018**, 7, e009217	6	34
177	The prediction of therapy-benefit for individual cardiovascular disease prevention: rationale, implications, and implementation. *Current Opinion in Lipidology*, **2018**, 29, 436-444	4.4	15
176	Routinely measured hematological parameters and prediction of recurrent vascular events in patients with clinically manifest vascular disease. *PLoS ONE*, **2018**, 13, e0202682	3.7	4
175	Variation in minimum desired cardiovascular disease-free longevity benefit from statin and antihypertensive medications: a cross-sectional study of patient and primary care physician perspectives. *BMJ Open*, **2018**, 8, e021309	3	8
174	Achieved LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia: A model that explores the efficacy of conventional and novel lipid-lowering therapy. *Journal of Clinical Lipidology*, **2018**, 12, 972-980.e1	4.9	11
173	Autosomal dominant familial dysbetalipoproteinemia: A pathophysiological framework and practical approach to diagnosis and therapy. *Journal of Clinical Lipidology*, **2017**, 11, 12-23.e1	4.9	20
172	Cerebral disease in a nationwide Dutch pseudoxanthoma elasticum cohort with a systematic review of the literature. *Journal of the Neurological Sciences*, **2017**, 373, 167-172	3.2	14
171	Relation between brown adipose tissue and measures of obesity and metabolic dysfunction in patients with cardiovascular disease. *Journal of Magnetic Resonance Imaging*, **2017**, 46, 497-504	5.6	39
170	Cost-Effectiveness of Intensifying Lipid-Lowering Therapy With Statins Based on Individual Absolute Benefit in Coronary Artery Disease Patients. *Journal of the American Heart Association*, **2017**, 6,	6	13
169	Relation between Kidney Length and Cardiovascular and Renal Risk in High-Risk Patients. *Clinical Journal of the American Society of Nephrology: CJASN*, **2017**, 12, 921-928	6.9	4
168	Familial dysbetalipoproteinemia: an underdiagnosed lipid disorder. *Current Opinion in Endocrinology, Diabetes and Obesity*, **2017**, 24, 133-139	4	39
167	Risk Factors for Recurrent Cardiovascular Events Before Age 65 Years or Within 2.5 Years of a Recent First Cardiovascular Event. *American Journal of Cardiology*, **2017**, 120, 167-173	3	2
166	Inter-arm systolic blood pressure differences, relations with future vascular events and mortality in patients with and without manifest vascular disease. *International Journal of Cardiology*, **2017**, 244, 271-276	3.2	17
165	Uniform data collection in routine clinical practice in cardiovascular patients for optimal care, quality control and research: The Utrecht Cardiovascular Cohort. *European Journal of Preventive Cardiology*, **2017**, 24, 840-847	3.9	7
164	Response by Kaasenbrood et al to Letter Regarding Article, "Distribution of Estimated 10-Year Risk of Recurrent Vascular Events and Residual Risk in a Secondary Prevention Population". *Circulation*, **2017**, 135, e820-e821	16.7	2
163	Letter by Westerink and Visseren Regarding Article, "Ezetimibe in Combination With Statins Ameliorates Endothelial Dysfunction in Coronary Arteries After Stenting: The CuVIC Trial (Effect of Cholesterol Absorption Inhibitor Usage on Target Vessel Dysfunction After Coronary Stenting), a Multicenter Randomized Controlled Trial". *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2017**,	9.4	1
162	Identification of vascular patients at very high risk for recurrent cardiovascular events: validation of the current ACC/AHA very high risk criteria. *European Heart Journal*, **2017**, 38, 3211-3218	9.5	23
161	Safety of Temporary Discontinuation of Antihypertensive Medication in Patients With Difficult-to-Control Hypertension. *Hypertension*, **2017**, 69, 927-932	8.5	13

160	Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk. *European Journal of Preventive Cardiology* , **2017**, 24, 951-961	3.9	15
159	Relation of Epicardial Adipose Tissue Radiodensity to Coronary Artery Calcium on Cardiac Computed Tomography in Patients at High Risk for Cardiovascular Disease. *American Journal of Cardiology*, **2017**, 119, 1359-1365	3	24
158	Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol. *New England Journal of Medicine*, **2017**, 376, 1430-1440	59.2	507
157	High ratios of kidney function to kidney size are related to mortality and kidney function decline in high-risk patients. *European Journal of Preventive Cardiology*, **2017**, 24, 926-933	3.9	9
156	Prevalence and severity of arterial calcifications in pseudoxanthoma elasticum (PXE) compared to hospital controls. Novel insights into the vascular phenotype of PXE. *Atherosclerosis*, **2017**, 256, 7-14	3.1	21
155	Impact of Selection Bias on Estimation of Subsequent Event Risk. *Circulation: Cardiovascular Genetics*, **2017**, 10,		19
154	Effect of adding bezafibrate to standard lipid-lowering therapy on post-fat load lipid levels in patients with familial dysbetalipoproteinemia. A randomized placebo-controlled crossover trial. *Journal of Lipid Research*, **2017**, 58, 2180-2187	6.3	11
153	Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials. *Cardiovascular Diabetology*, **2017**, 16, 134	8.7	62
152	Identifying treatment response to antihypertensives in patients with obesity-related hypertension. *Clinical Hypertension*, **2017**, 23, 20	4.8	3
151	Prevalence and clinical characteristics of apparent therapy-resistant hypertension in patients with cardiovascular disease: a cross-sectional cohort study in secondary care. *BMJ Open*, **2017**, 7, e016692	3	7
150	Adult derived genetic blood pressure scores and blood pressure measured in different body postures in young children. *European Journal of Preventive Cardiology*, **2017**, 24, 320-327	3.9	4
149	Measures of chronic kidney disease and risk of incident peripheral artery disease: a collaborative meta-analysis of individual participant data. *Lancet Diabetes and Endocrinology,the*, **2017**, 5, 718-728	18.1	68
148	Physical Activity and Characteristics of the Carotid Artery Wall in High-Risk Patients-The SMART (Second Manifestations of Arterial Disease) Study. *Journal of the American Heart Association*, **2017**, 6,	6	7
147	SPRINT trial: It's not just the blood pressure!. *European Journal of Preventive Cardiology*, **2017**, 24, 1482-1484	3.9	5
146	Incidence of cardiovascular events and vascular interventions in patients with type 2 diabetes. *International Journal of Cardiology*, **2017**, 248, 301-307	3.2	20
145	Trends in comorbidity in patients hospitalised for cardiovascular disease. *International Journal of Cardiology*, **2017**, 248, 382-388	3.2	19
144	Effect modification in the association between glycated haemoglobin and cardiovascular disease and mortality in patients with type 2 diabetes. *Diabetes, Obesity and Metabolism*, **2017**, 19, 320-328	6.7	2
143	Personalized absolute benefit of statin treatment for primary or secondary prevention of vascular disease in individual elderly patients. *Clinical Research in Cardiology*, **2017**, 106, 58-68	6.1	17

142	Relation between cardiovascular disease risk factors and epicardial adipose tissue density on cardiac computed tomography in patients at high risk of cardiovascular events. *European Journal of Preventive Cardiology*, **2017**, 24, 660-670	3.9	34
141	Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, Triglycerides, and Apolipoprotein B and Cardiovascular Risk in Patients With Manifest Arterial Disease. *American Journal of Cardiology*, **2016**, 118, 804-810	3	15
140	Plasma CTGF is independently related to an increased risk of cardiovascular events and mortality in patients with atherosclerotic disease: the SMART study. *Growth Factors*, **2016**, 34, 149-58	1.6	12
139	How to translate clinical trial results into gain in healthy life expectancy for individual patients. *BMJ, The*, **2016**, 352, i1548	5.9	31
138	Tendon xanthomas: Not always familial hypercholesterolemia. *Journal of Clinical Lipidology*, **2016**, 10, 1262-5	4.9	11
137	Novel Biomarkers to Improve the Prediction of Cardiovascular Event Risk in Type 2 Diabetes Mellitus. *Journal of the American Heart Association*, **2016**, 5,	6	44
136	Cause-specific mortality and years of life lost in patients with different manifestations of vascular disease. *European Journal of Preventive Cardiology*, **2016**, 23, 160-9	3.9	10
135	Reliability and agreement of adipose tissue fat fraction measurements with water-fat MRI in patients with manifest cardiovascular disease. *NMR in Biomedicine*, **2016**, 29, 48-56	4.4	17
134	Estimated cardiovascular relative risk reduction from fixed-dose combination pill (polypill) treatment in a wide range of patients with a moderate risk of cardiovascular disease. *European Journal of Preventive Cardiology*, **2016**, 23, 1289-97	3.9	11
133	The relation between apolipoprotein E (APOE) genotype and peripheral artery disease in patients at high risk for cardiovascular disease. *Atherosclerosis*, **2016**, 246, 187-92	3.1	17
132	Bisphosphonates for cardiovascular risk reduction: A systematic review and meta-analysis. *Atherosclerosis*, **2016**, 252, 106-115	3.1	75
131	The influence of baseline risk on the relation between HbA1c and risk for new cardiovascular events and mortality in patients with type 2 diabetes and symptomatic cardiovascular disease. *Cardiovascular Diabetology*, **2016**, 15, 101	8.7	15
130	The Effects of Secondary Cardiovascular Prevention on Cancer Risk in Patients With Manifest Vascular Disease. *Journal of the American College of Cardiology*, **2016**, 68, 2588-2589	15.1	2
129	Abdominal fat and blood pressure in healthy young children. *Journal of Hypertension*, **2016**, 34, 1796-803	1.9	8
128	HDL Cholesterol as a Residual Risk Factor for Vascular Events and All-Cause Mortality in Patients With Type 2 Diabetes. *Diabetes Care*, **2016**, 39, 1424-30	14.6	25
127	Development and Validation of a Model to Predict Absolute Vascular Risk Reduction by Moderate-Intensity Statin Therapy in Individual Patients With Type 2 Diabetes Mellitus: The Anglo Scandinavian Cardiac Outcomes Trial, Antihypertensive and Lipid-Lowering Treatment to Prevent	5.8	8
126	Pemetrexed plus carboplatin versus pemetrexed in pretreated patients with advanced non-squamous non-small-cell lung cancer: treating the right patients based on individualized treatment effect prediction. *Annals of Oncology*, **2016**, 27, 1280-6	10.3	3
125	Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes. *Diabetologia*, **2016**, 59, 2603-2612	10.3	6

124	Distribution of Estimated 10-Year Risk of Recurrent Vascular Events and Residual Risk in a Secondary Prevention Population. *Circulation*, **2016**, 134, 1419-1429	16.7	104
123	Response to Comment on Sharif et al. HDL Cholesterol as a Residual Risk Factor for Vascular Events and All-Cause Mortality in Patients With Type 2 Diabetes. Diabetes Care 2016;39:1424-1430. *Diabetes Care*, **2016**, 39, e190-1	14.6	
122	Metabolic consequences of adipose tissue dysfunction and not adiposity per se increase the risk of cardiovascular events and mortality in patients with type 2 diabetes. *International Journal of Cardiology*, **2016**, 222, 72-77	3.2	11
121	Prevalence and risk of cardiovascular risk factors and events in offspring of patients at high vascular risk and effect of location of parental vascular disease. *International Journal of Cardiology*, **2015**, 195, 195-202	3.2	2
120	Paternal or maternal history of cardiovascular disease and the risk of cardiovascular disease in offspring. A systematic review and meta-analysis. *International Journal of Cardiology*, **2015**, 179, 409-16	3.2	20
119	Carotid Intima Media Thickness in Mainly Female HIV-Infected Subjects in Rural South Africa: Association With Cardiovascular but Not HIV-Related Factors. *Clinical Infectious Diseases*, **2015**, 61, 1606-14	11.6	29
118	Effect of Type 2 Diabetes on Recurrent Major Cardiovascular Events for Patients With Symptomatic Vascular Disease at Different Locations. *Diabetes Care*, **2015**, 38, 1528-35	14.6	16
117	Extracellular vesicle-derived CD14 is independently associated with the extent of cardiovascular disease burden in patients with manifest vascular disease. *European Journal of Preventive Cardiology*, **2015**, 22, 451-7	3.9	12
116	Vascular risk factors, vascular disease, lipids and lipid targets in patients with familial dysbetalipoproteinemia: a European cross-sectional study. *Atherosclerosis*, **2015**, 240, 90-7	3.1	31
115	The relation between the presence of cardiovascular disease and vascular risk factors in offspring and the occurrence of new vascular events in their parents already at high vascular risk. *American Heart Journal*, **2015**, 170, 744-752.e2	4.9	3
114	Hypertensive Target Organ Damage and Longitudinal Changes in Brain Structure and Function: The Second Manifestations of Arterial Disease-Magnetic Resonance Study. *Hypertension*, **2015**, 66, 1152-8	8.5	19
113	Presence of albuminuria predicts left ventricular mass in patients with chronic systemic arterial hypertension. *European Journal of Clinical Investigation*, **2015**, 45, 550-6	4.6	6
112	Association between CETP gene polymorphism, insulin resistance and risk of diabetes mellitus in patients with vascular disease. *Atherosclerosis*, **2015**, 242, 605-10	3.1	7
111	The relation between HbA1c and cardiovascular events in patients with type 2 diabetes with and without vascular disease. *Diabetes Care*, **2015**, 38, 1930-6	14.6	26
110	Body weight, metabolic dysfunction, and risk of type 2 diabetes in patients at high risk for cardiovascular events or with manifest cardiovascular disease: a cohort study. *Diabetes Care*, **2015**, 38, 1945-51	14.6	15
109	Individualised prediction of alternate-day aspirin treatment effects on the combined risk of cancer, cardiovascular disease and gastrointestinal bleeding in healthy women. *Heart*, **2015**, 101, 369-76	5.1	36
108	Allergies are associated with arterial changes in young children. *European Journal of Preventive Cardiology*, **2015**, 22, 1480-7	3.9	6
107	Predicting the effects of blood pressure-lowering treatment on major cardiovascular events for individual patients with type 2 diabetes mellitus: results from Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation. *Hypertension*, **2015**, 65, 115-21	8.5	21

106	Physical Activity and Vascular Events and Mortality in Patients with Vascular Disease. *Medicine and Science in Sports and Exercise*, **2015**, 47, 2359-65	1.2	4
105	The relation between body iron stores and adipose tissue function in patients with manifest vascular disease. *European Journal of Clinical Investigation*, **2015**, 45, 1127	4.6	
104	Research update for articles published in EJCI in 2013. *European Journal of Clinical Investigation*, **2015**, 45, 1005-16	4.6	0
103	FP342COMBINING KIDNEY FUNCTION AND SIZE AND ITS RELATION TO KIDNEY FUNCTION DECLINE, CARDIOVASCULAR EVENTS AND ALL-CAUSE MORTALITY IN PATIENTS WITH CLINICAL MANIFEST VASCULAR DISEASE. *Nephrology Dialysis Transplantation*, **2015**, 30, iii182-iii183	4.3	
102	Relation Between Circulating Inflammatory Chemokines and Vascular Characteristics in Healthy, Young Children. *Journal of the American Heart Association*, **2015**, 4,	6	11
101	Effect of statin therapy on incident type 2 diabetes mellitus in patients with clinically manifest vascular disease. *American Journal of Cardiology*, **2015**, 115, 441-6	3	15
100	Inflammatory characteristics of distinct abdominal adipose tissue depots relate differently to metabolic risk factors for cardiovascular disease: distinct fat depots and vascular risk factors. *Atherosclerosis*, **2015**, 239, 419-27	3.1	55
99	Prediction of absolute risk reduction of cardiovascular events with perindopril for individual patients with stable coronary artery disease - results from EUROPA. *International Journal of Cardiology*, **2015**, 182, 194-9	3.2	9
98	Incremental value of a genetic risk score for the prediction of new vascular events in patients with clinically manifest vascular disease. *Atherosclerosis*, **2015**, 239, 451-8	3.1	27
97	Personalized cardiovascular disease prevention by applying individualized prediction of treatment effects. *European Heart Journal*, **2014**, 35, 837-43	9.5	43
96	An oral mixed fat load is followed by a modest anti-inflammatory adipocytokine response in overweight patients with metabolic syndrome. *Lipids*, **2014**, 49, 247-54	1.6	10
95	Extracellular vesicle markers in relation to obesity and metabolic complications in patients with manifest cardiovascular disease. *Cardiovascular Diabetology*, **2014**, 13, 37	8.7	78
94	Effect of extracellular vesicles of human adipose tissue on insulin signaling in liver and muscle cells. *Obesity*, **2014**, 22, 2216-23	8	97
93	Premature atherosclerosis, extremely low HDL-cholesterol and concurrent defects in APOA1 and ABCA1 genes: a family case report. *International Journal of Cardiology*, **2014**, 177, e19-21	3.2	5
92	Extracellular vesicle protein CD14 relates to common carotid intima-media thickness in eight-year-old children. *Atherosclerosis*, **2014**, 236, 270-6	3.1	7
91	The role of T cells in the development of cardiovascular disease in HIV-infected patients. *Atherosclerosis*, **2014**, 237, 92-8	3.1	17
90	Secretion of adipocytokines by perivascular adipose tissue near stenotic and non-stenotic coronary artery segments in patients undergoing CABG. *Atherosclerosis*, **2014**, 233, 242-7	3.1	28
89	Rs964184 (APOA5-A4-C3-A1) is related to elevated plasma triglyceride levels, but not to an increased risk for vascular events in patients with clinically manifest vascular disease. *PLoS ONE*, **2014**, 9, e101082	3.7	15

88	The evening versus morning polypill utilization study: the TEMPUS rationale and design. *European Journal of Preventive Cardiology*, **2014**, 21, 425-33	3.9	8
87	Relationship between leptin and lung function in young healthy children. *European Respiratory Journal*, **2014**, 43, 1189-92	13.6	19
86	Homocysteine and progression of generalized small-vessel disease: the SMART-MR Study. *Neurology*, **2014**, 82, 777-83	6.5	44
85	Extracellular vesicle protein levels are related to brain atrophy and cerebral white matter lesions in patients with manifest vascular disease: the SMART-MR study. *BMJ Open*, **2014**, 4, e003824	3	17
84	Feasibility and reproducibility of free fatty acid profiling in abdominal adipose tissue with 1H-magnetic resonance spectroscopy at 3 T: differences between lean and obese individuals. *Journal of Magnetic Resonance Imaging*, **2014**, 40, 423-31	5.6	7
83	The relation between resting heart rate and cancer incidence, cancer mortality and all-cause mortality in patients with manifest vascular disease. *Cancer Epidemiology*, **2014**, 38, 715-21	2.8	17
82	LDL-c-linked SNPs are associated with LDL-c and myocardial infarction despite lipid-lowering therapy in patients with established vascular disease. *European Journal of Clinical Investigation*, **2014**, 44, 184-91	4.6	9
81	Human adipocyte extracellular vesicles in reciprocal signaling between adipocytes and macrophages. *Obesity*, **2014**, 22, 1296-308	8	102
80	Dementia and cognitive decline in type 2 diabetes and prediabetic stages: towards targeted interventions. *Lancet Diabetes and Endocrinology,the*, **2014**, 2, 246-55	18.1	331
79	Parental history and the risk of subsequent vascular events in patients with clinically manifest vascular disease: the effects of sex of the parent and vascular disease location. *Atherosclerosis*, **2014**, 234, 129-35	3.1	8
78	The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) and the risk of vascular morbidity and mortality in patients with coronary artery disease. *American Heart Journal*, **2013**, 166, 282-289.e1	4.9	38
77	Blood pressure and progression of brain atrophy: the SMART-MR Study. *JAMA Neurology*, **2013**, 70, 1046-53	11.2	33
76	Plasma triglyceride levels increase the risk for recurrent vascular events independent of LDL-cholesterol or nonHDL-cholesterol. *International Journal of Cardiology*, **2013**, 167, 403-8	3.2	15
75	Asymptomatic carotid artery stenosis and the risk of ischemic stroke according to subtype in patients with clinical manifest arterial disease. *Stroke*, **2013**, 44, 1002-7	6.7	74
74	C-reactive protein and incident diabetes in patients with arterial disease. *European Journal of Clinical Investigation*, **2013**, 43, 1052-9	4.6	5
73	Biomarkers. Screening for C-reactive protein in CVD prediction. *Nature Reviews Cardiology*, **2013**, 10, 12-4	14.8	7
72	The risk of resting heart rate on vascular events and mortality in vascular patients. *International Journal of Cardiology*, **2013**, 168, 1410-5	3.2	22
71	Microvesicle protein levels are associated with increased risk for future vascular events and mortality in patients with clinically manifest vascular disease. *International Journal of Cardiology*, **2013**, 168, 2358-63	3.2	65

70	High-dose statin monotherapy versus low-dose statin/ezetimibe combination on fasting and postprandial lipids and endothelial function in obese patients with the metabolic syndrome: The PANACEA study. *Atherosclerosis*, **2013**, 227, 118-24	3.1	28
69	Low high-density lipoprotein cholesterol is not a risk factor for recurrent vascular events in patients with vascular disease on intensive lipid-lowering medication. *Journal of the American College of Cardiology*, **2013**, 62, 1834-41	15.1	34
68	Relationship between myocardial bridges and reduced coronary atherosclerosis in patients with angina pectoris. *International Journal of Cardiology*, **2013**, 167, 883-8	3.2	18
67	Renal impairment and all-cause mortality in cardiovascular disease: effect modification by type 2 diabetes mellitus. *European Journal of Clinical Investigation*, **2013**, 43, 198-207	4.6	10
66	Adiponectin and incident coronary heart disease and stroke. A systematic review and meta-analysis of prospective studies. *Obesity Reviews*, **2013**, 14, 555-67	10.6	54
65	The daily 10 kcal expenditure deficit: a before-and-after study on low-cost interventions in the work environment. *BMJ Open*, **2013**, 3,	3	8
64	Excess early postnatal weight gain leads to thicker and stiffer arteries in young children. *Journal of Clinical Endocrinology and Metabolism*, **2013**, 98, 794-801	5.6	31
63	The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) in clinical practice in patients with vascular diseases or type 2 diabetes mellitus. *European Journal of Preventive Cardiology*, **2013**, 20, 771-8	3.9	13
62	Cancer risk in patients with manifest vascular disease: effects of smoking, obesity, and metabolic syndrome. *Cancer Epidemiology Biomarkers and Prevention*, **2013**, 22, 1267-77	4	38
61	Development and validation of a prediction rule for recurrent vascular events based on a cohort study of patients with arterial disease: the SMART risk score. *Heart*, **2013**, 99, 866-72	5.1	103
60	Research update for articles published in EJCI in 2011. *European Journal of Clinical Investigation*, **2013**, 43, 1097-1110	4.6	2
59	The relation between body iron stores and adipose tissue function in patients with manifest vascular disease. *European Journal of Clinical Investigation*, **2013**, 43, 1240-9	4.6	4
58	Hepatocyte growth factor and interferon-inducible protein-10 are related to visceral adiposity. *European Journal of Clinical Investigation*, **2013**, 43, 369-78	4.6	9
57	High-dose statin therapy in patients with stable coronary artery disease: treating the right patients based on individualized prediction of treatment effect. *Circulation*, **2013**, 127, 2485-93	16.7	34
56	Age-related differences in abdominal fat distribution in premenopausal and postmenopausal women with cardiovascular disease. *Menopause*, **2013**, 20, 409-17	2.5	13
55	Hypertensive target organ damage and the risk for vascular events and all-cause mortality in patients with vascular disease. *Journal of Hypertension*, **2013**, 31, 492-99; discussion 499-500	1.9	25
54	Differential effects of renin-angiotensin-aldosterone system inhibition, sympathoinhibition and diuretic therapy on endothelial function and blood pressure in obesity-related hypertension: a double-blind, placebo-controlled cross-over trial. *Journal of Hypertension*, **2013**, 31, 393-403	1.9	37
53	Serum angiotensin-converting enzyme and recurrent vascular events. The SMART-MR study. *Atherosclerosis*, **2012**, 224, 486-91	3.1	8

52	Coronary perivascular adipose tissue characteristics are related to atherosclerotic plaque size and composition. A post-mortem study. *Atherosclerosis*, **2012**, 225, 99-104	3.1	53
51	Relation between thyroid-stimulating hormone and the occurrence of cardiovascular events and mortality in patients with manifest vascular diseases. *European Journal of Preventive Cardiology*, **2012**, 19, 864-73	3.9	18
50	Increased visceral adipose tissue is associated with increased resting heart rate in patients with manifest vascular disease. *Obesity*, **2012**, 20, 834-41	8	16
49	The prevalence of obesity-related hypertension and risk for new vascular events in patients with vascular diseases. *Obesity*, **2012**, 20, 2118-23	8	12
48	Hypertension and longitudinal changes in cerebral blood flow: the SMART-MR study. *Annals of Neurology*, **2012**, 71, 825-33	9.4	118
47	Excess early postnatal weight gain leads to increased abdominal fat in young children. *International Journal of Pediatrics (United Kingdom)*, **2012**, 2012, 141656	2.1	12
46	Relation between blood pressure and vascular events and mortality in patients with manifest vascular disease: J-curve revisited. *Hypertension*, **2012**, 59, 14-21	8.5	101
45	PS15 - 73. Identification and characterization of microvesicles secreted by human SGBS-adipocytes. *Nederlands Tijdschrift Voor Diabetologie*, **2012**, 10, 150-151	0	
44	Prediction model with metabolic syndrome to predict recurrent vascular events in patients with clinically manifest vascular diseases. *European Journal of Preventive Cardiology*, **2012**, 19, 1486-95	3.9	2
43	Relation between adiposity and hypertension persists after onset of clinically manifest arterial disease. *Journal of Hypertension*, **2012**, 30, 2331-7	1.9	4
42	Perivascular adipose tissue as a cause of atherosclerosis. *Atherosclerosis*, **2011**, 214, 3-10	3.1	178
41	The relation between thyroid-stimulating hormone and measures of adiposity in patients with manifest vascular disease. *European Journal of Clinical Investigation*, **2011**, 41, 159-66	4.6	17
40	Insulin resistance increases the occurrence of new cardiovascular events in patients with manifest arterial disease without known diabetes. the SMART study. *Cardiovascular Diabetology*, **2011**, 10, 100	8.7	24
39	Estimating treatment effects for individual patients based on the results of randomised clinical trials. *BMJ, The*, **2011**, 343, d5888	5.9	94
38	The effect of self-efficacy on cardiovascular lifestyle. *European Journal of Cardiovascular Nursing*, **2011**, 10, 180-6	3.3	49
37	The association between breastfeeding and the cardiovascular system in early childhood. *American Journal of Clinical Nutrition*, **2011**, 93, 712-8	7	37
36	Aspirin for primary prevention of vascular events in women: individualized prediction of treatment effects. *European Heart Journal*, **2011**, 32, 2962-9	9.5	31
35	Trends in vascular risk factors and medication use in patients with various manifestations of vascular diseases or type 2 diabetes mellitus from 1996 to 2007: the Second Manifestations of ARTerial disease study. *European Journal of Cardiovascular Prevention and Rehabilitation*, **2010**, 17, 628-36		10

34	Patients with coronary, cerebrovascular or peripheral arterial obstructive disease differ in risk for new vascular events and mortality: the SMART study. *European Journal of Cardiovascular Prevention and Rehabilitation*, **2010**, 17, 424-30		34
33	The effect of a self-management intervention to reduce vascular risk factors in patients with manifestations of vascular diseases. *European Journal of Cardiovascular Nursing*, **2010**, 9, 132-9	3.3	6
32	Acute and chronic renal artery stenosis. *European Heart Journal*, **2010**, 31, 14	9.5	1
31	A prediction model for left ventricular mass in patients at high cardiovascular risk. *European Journal of Cardiovascular Prevention and Rehabilitation*, **2010**, 17, 621-7		9
30	Increased visceral adipose tissue mass is associated with increased C-reactive protein in patients with manifest vascular diseases. *Atherosclerosis*, **2010**, 212, 274-80	3.1	46
29	Blood pressure, cerebral blood flow, and brain volumes. The SMART-MR study. *Journal of Hypertension*, **2010**, 28, 1498-505	1.9	53
28	Letter by Westerink and Visseren regarding article, "Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation". *Circulation*, **2009**, 120, e66; author reply e69-70	16.7	1
27	Blood pressure and progression of cerebral atrophy in patients with vascular disease. *American Journal of Hypertension*, **2009**, 22, 1183-9	2.3	10
26	Social support and change in vascular risk factors in patients with clinical manifestations of vascular diseases. *European Journal of Cardiovascular Nursing*, **2009**, 8, 137-43	3.3	4
25	Obesity and cancer: the role of dysfunctional adipose tissue. *Cancer Epidemiology Biomarkers and Prevention*, **2009**, 18, 2569-78	4	515
24	The effect of statin alone or in combination with ezetimibe on postprandial lipoprotein composition in obese metabolic syndrome patients. *Atherosclerosis*, **2009**, 202, 216-24	3.1	35
23	Lipid-lowering therapy does not affect the postprandial drop in high density lipoprotein-cholesterol (HDL-c) plasma levels in obese men with metabolic syndrome: a randomized double blind crossover trial. *Clinical Endocrinology*, **2008**, 69, 870-7	3.4	16
22	Relation of epicardial and pericoronary fat to coronary atherosclerosis and coronary artery calcium in patients undergoing coronary angiography. *American Journal of Cardiology*, **2008**, 102, 380-5	3	206
21	Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. *European Heart Journal*, **2008**, 29, 2959-71	9.5	980
20	Quantification of epicardial and peri-coronary fat using cardiac computed tomography; reproducibility and relation with obesity and metabolic syndrome in patients suspected of coronary artery disease. *Atherosclerosis*, **2008**, 197, 896-903	3.1	194
19	Metabolic syndrome and incidence of type 2 diabetes in patients with manifest vascular disease. *Diabetes and Vascular Disease Research*, **2008**, 5, 114-22	3.3	21
18	The effects of low-dose simvastatin and ezetimibe compared to high-dose simvastatin alone on post-fat load endothelial function in patients with metabolic syndrome: a randomized double-blind crossover trial. *Journal of Cardiovascular Pharmacology*, **2008**, 52, 145-50	3.1	37
17	Metabolic syndrome and the risk of new vascular events and all-cause mortality in patients with coronary artery disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm. *European Heart Journal*, **2008**, 29, 213-23	9.5	52

16	Induction of Insulin Resistance by Adipokines in Human Megakaryocytes. *Blood*, **2008**, 112, 5390-5390	2.2	
15	Abdominal fat and risk of coronary heart disease in patients with peripheral arterial disease. *Obesity*, **2007**, 15, 1623-30	8	5
14	The operative risk factors in the metabolic syndrome: is it lipids and high BP or are there direct vascular effects of insulin resistance and obesity. *Current Diabetes Reports*, **2007**, 7, 74-81	5.6	2
13	Asymptomatic carotid artery stenosis and the risk of new vascular events in patients with manifest arterial disease: the SMART study. *Stroke*, **2007**, 38, 1470-5	6.7	174
12	Low plasma levels of adiponectin are associated with low risk for future cardiovascular events in patients with clinical evident vascular disease. *American Heart Journal*, **2007**, 154, 750.e1-7	4.9	23
11	The effect of leisure-time physical activity on the presence of metabolic syndrome in patients with manifest arterial disease. The SMART study. *American Heart Journal*, **2007**, 154, 1146-52	4.9	22
10	Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. *Lancet, The*, **2007**, 370, 153-160	40	385
9	The course of vascular risk factors and the occurrence of vascular events in patients with symptomatic peripheral arterial disease. *Journal of Vascular Surgery*, **2007**, 45, 47-54	3.5	32
8	TNF-alpha induces endothelial dysfunction in diabetic adults, an effect reversible by the PPAR-gamma agonist pioglitazone. *European Heart Journal*, **2006**, 27, 1605-9	9.5	65
7	A randomized, controlled trial for risk factor reduction in patients with symptomatic vascular disease: the multidisciplinary Vascular Prevention by Nurses Study (VENUS). *European Journal of Cardiovascular Prevention and Rehabilitation*, **2006**, 13, 996-1003		29
6	Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes. *Journal of Cardiovascular Pharmacology*, **2005**, 46, 773-8	3.1	99
5	The metabolic syndrome is associated with advanced vascular damage in patients with coronary heart disease, stroke, peripheral arterial disease or abdominal aortic aneurysm. *European Heart Journal*, **2004**, 25, 342-8	9.5	178
4	Intracellular labile iron modulates adhesion of human monocytes to human endothelial cells. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2004**, 24, 2257-62	9.4	42
3	Prevalence of the metabolic syndrome in patients with coronary heart disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm. *Atherosclerosis*, **2004**, 173, 363-9	3.1	138
2	Iron chelation and hydroxyl radical scavenging reduce the inflammatory response of endothelial cells after infection with Chlamydia pneumoniae or influenza A. *European Journal of Clinical Investigation*, **2002**, 32 Suppl 1, 84-90	4.6	39
1	Metabolic and additional vascular effects of thiazolidinediones. *Drugs*, **2002**, 62, 1463-80	12.1	222